Back to overview

Nobel Prize 2024 Awarded for Discovery of microRNAs

This year’s Nobel Prize in Physiology or Medicine recognizes the discovery of microRNAs. These small RNA molecules are central to Neumirna Therepeutics approach to developing treatments for neurological diseases.

The 2024 Nobel Prize in Physiology or Medicine has been awarded to Victor Ambros and Gary Ruvkun for their discovery of microRNAs – a previously unknown class of small RNA molecules that play a central role in gene regulation.

Their work revealed that microRNAs are critical for how cells develop, communicate, and function. Since their discovery, microRNAs have become a key focus in biomedical research, with implications ranging from developmental biology to chronic and degenerative diseases.

At Neumirna, this recognition holds particular significance. Our therapeutic platform is based on the targeting of microRNAs to develop disease-modifying treatments for complex neurological disorders. The work of Ambros and Ruvkun laid the scientific groundwork for this new therapeutic approach.

We extend our congratulations to the laureates and to the broader scientific community working in the field of RNA biology. Their discovery continues to inspire and enable new frontiers in medicine.

Read the official announcement here.

Development
17.9.2025
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer
We are excited to announce that Ellen K. Donnelly, Ph.D. has been appointed Chief Executive Officer of Neumirna Therapeutics.
Read full article
Development
8.7.2025
Neumirna Appoints Ina Brünig-Traebert as Chief Development Officer
With a proven track record in RNA therapies, Ina will guide Neumirna’s transition into clinical-stage development.
Read full article
Development
8.5.2025
Neumirna Strengthens Board with Andreas Wallnöfer as Independent Board Member
Neumirna Therapeutics has named Andreas Wallnöfer as an independent member of its Board of Directors.
Read full article